Clinical Trials Logo

Filter by:
NCT ID: NCT01406938 Completed - Clinical trials for Moderate to Severe Plaque-type Psoriasis

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

SCULPTURE
Start date: August 2011
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.

NCT ID: NCT01406574 Completed - Clinical trials for Hepatocellular Carcinoma

Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma

Start date: July 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is: Phase1: To evaluate the safety and determine the recommended dose (RD) Phase2: To evaluate the efficacy

NCT ID: NCT01404390 Completed - Neoplasms Clinical Trials

Japanese BAY80-6946 Monotherapy Phase I Study

Start date: August 18, 2011
Phase: Phase 1
Study type: Interventional

This study will be conducted as an open label, single centre, Phase I study of PI3K (phosphatidyl inositol 3 kinase) inhibitor BAY80-6946 in Japanese patients with advanced or refractory solid tumours. The eligible subjects will be dosed intravenously at Day 1, Day 8 and Day 15 with three weeks on and one week off in each treatment cycle.

NCT ID: NCT01403818 Completed - Healthy Clinical Trials

A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration

Start date: June 2011
Phase: Phase 1
Study type: Interventional

This study is to assess the pharmacokinetic interaction between ASP1941 and Mitiglinide calcium hydrate in healthy volunteers.

NCT ID: NCT01403805 Completed - Pneumonia Clinical Trials

Effects of the Oral Care With Vaccines for Pneumonia in Elderly; Going Home Together Both Physician and Dentist

Start date: November 2009
Phase: N/A
Study type: Interventional

Prospective study comparing the effects of interventions (combined oral care and pneumococcal plus influenza vaccinations) in preventing pneumonia and increasing the survival rate from pneumonia.

NCT ID: NCT01403025 Completed - Clinical trials for Diabetes Mellitus, Type 2

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Start date: July 19, 2011
Phase: N/A
Study type: Observational

This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).

NCT ID: NCT01402986 Completed - Asthma Clinical Trials

A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma

Start date: August 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma

NCT ID: NCT01401530 Completed - Clinical trials for Peripheral T-Cell Lymphoma

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Start date: July 2011
Phase: Phase 1
Study type: Interventional

The purpose of this Phase 1 study is to determine the maximum tolerated dose (MTD) through observation of dose limiting toxicity (DLT), which is in advance defined, in patients with peripheral or cutaneous T-cell lymphoma.

NCT ID: NCT01401504 Completed - Solid Tumor Clinical Trials

Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

Start date: May 2011
Phase: Phase 1
Study type: Interventional

A study to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors).

NCT ID: NCT01401114 Completed - Clinical trials for Osteoporosis, Postmenopausal

Wellnara Post-marketing Surveillance in Japan

WELLNARA
Start date: March 2009
Phase: N/A
Study type: Observational

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Wellnara for postmenopausal osteoporosis. The objective of this study is to assess safety and efficacy of using Wellnara in clinical practice. A total 400 patients will be recruited and followed 3 years since starting Wellnara administration.